Diagnosing lymphohistiocytic hemophagocytosis in intensive care patients with liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational review of adult ICU patients at Hautepierre Hospital (CHU de Strasbourg) from January 1, 2014 to December 31, 2024. Researchers will extract clinical and laboratory data to calculate HScore components (including ferritin, triglycerides, and cytopenias) and compare HScore results with clinical diagnoses and outcomes. The cohort focuses on patients with hepatocellular insufficiency and/or cirrhosis who meet at least three biological signs suggestive of HLH. No investigational treatments are administered as this analysis uses existing medical records.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient (≥18 years old)
* Patient admitted to the intensive care unit at Hautepierre Hospital, Strasbourg University Hospital, between January 1, 2014, and December 31, 2024
* At least 3 biological signs of HLH:

  * ferritin \> 2000 ng/mL
  * triglycerides \> 1.5 g/L
  * at least one cytopenia (leukocytes ≤ 5000 G/L, platelets ≤ 110 G/L, hemoglobin ≤ 9.2 g/dL).

Exclusion Criteria:

Refusal to participate in the study

Where it's running

• Médecine intensive - Réanimation - CHU de Strasbourg - France
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Antonin HUGEROT, MD
• Email: antonin.hugerot@chru-strasbourg.fr
• Phone: 33 3 88 12 79 24

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and how the drug behaves in adults with moderate to severe liver impairment

  This study tests the safety and how INCB123667 moves through the body when taken by adults with moderate to severe liver impairment.

  Recruiting at 4 sites Phase 1 Incyte Corporation · Chandler, Arizona and 3 other locations · NCT07559474

• Bile acid and gut microbiota changes in people with hepatitis D starting bulevirtide

  This project will see if starting bulevirtide changes bile acids and gut bacteria in adults with chronic hepatitis D who are already on hepatitis B therapy.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07429864

• Eloralintide in people with and without liver damage

  This Phase 1 study will test how the medicine eloralintide (LY3841136) is absorbed, processed, and tolerated in adults with healthy livers and in those with mild, moderate, or severe liver damage.

  Recruiting at 3 sites Phase 1 Eli Lilly and Company · Orlando, Florida and 2 other locations · NCT07401862

• Echocardiography-guided intensive care for septic shock in people with cirrhosis

  This study will try using bedside ultrasound (POCUS) to guide fluid and blood-pressure treatment in adults with cirrhosis who develop sepsis-related low blood pressure.

  Recruiting Post Graduate Institute of Medical Education and Research, Chandigarh · Chandigarh · NCT07286643

• Understanding social and health needs of people with chronic liver disease in outpatient care

  This project will see how common social needs are and whether adults with chronic liver disease want their outpatient providers to help with them.

  Recruiting Indiana University · Indianapolis, Indiana · NCT07191886

• How LY3537031 is processed and tolerated in people with normal or impaired liver function

  This trial will test how LY3537031 is absorbed, distributed, and cleared and whether it is safe when given under the skin to adults with normal liver function and to adults with mild, moderate, or severe liver impairment.

  Recruiting at 3 sites Phase 1 Eli Lilly and Company · Kistarcsa and 2 other locations · NCT07165002

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.